These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36732163)

  • 1. Route and antigen shape immunity to dmLT-adjuvanted vaccines to a greater extent than biochemical stress or formulation excipients.
    Stone AE; Rambaran S; Trinh IV; Estrada M; Jarand CW; Williams BS; Murrell AE; Huerter CM; Bai W; Palani S; Nakanishi Y; Laird RM; Poly FM; Reed WF; White JA; Norton EB
    Vaccine; 2023 Feb; 41(9):1589-1601. PubMed ID: 36732163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.
    Holmgren J; Bourgeois L; Carlin N; Clements J; Gustafsson B; Lundgren A; Nygren E; Tobias J; Walker R; Svennerholm AM
    Vaccine; 2013 May; 31(20):2457-64. PubMed ID: 23541621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study.
    Lundgren A; Bourgeois L; Carlin N; Clements J; Gustafsson B; Hartford M; Holmgren J; Petzold M; Walker R; Svennerholm AM
    Vaccine; 2014 Dec; 32(52):7077-84. PubMed ID: 25444830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intradermal or Sublingual Delivery and Heat-Labile Enterotoxin Proteins Shape Immunologic Responses to a CFA/I Fimbria-Derived Subunit Antigen Vaccine against Enterotoxigenic Escherichia coli.
    Maciel M; Bauer D; Baudier RL; Bitoun J; Clements JD; Poole ST; Smith MA; Kaminski RW; Savarino SJ; Norton EB
    Infect Immun; 2019 Nov; 87(11):. PubMed ID: 31427449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant effect of enterotoxigenic
    Seo H; Lu T; Mani S; Bourgeois AL; Walker R; Sack DA; Zhang W
    Hum Vaccin Immunother; 2020; 16(2):419-425. PubMed ID: 31361177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization.
    Bernstein DI; Pasetti MF; Brady R; Buskirk AD; Wahid R; Dickey M; Cohen M; Baughman H; El-Khorazaty J; Maier N; Sztein MB; Baqar S; Bourgeois AL
    Vaccine; 2019 Jan; 37(4):602-611. PubMed ID: 30563789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. U-Omp19 from Brucella abortus increases dmLT immunogenicity and improves protection against Escherichia coli heat-labile toxin (LT) oral challenge.
    Coria LM; Martinez FL; Bruno LA; Pasquevich KA; Cassataro J
    Vaccine; 2020 Jul; 38(32):5027-5035. PubMed ID: 32536545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and Protective Efficacy against Enterotoxigenic Escherichia coli Colonization following Intradermal, Sublingual, or Oral Vaccination with EtpA Adhesin.
    Luo Q; Vickers TJ; Fleckenstein JM
    Clin Vaccine Immunol; 2016 Jul; 23(7):628-37. PubMed ID: 27226279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized placebo-controlled trial.
    Crothers JW; Ross Colgate E; Cowan KJ; Dickson DM; Walsh M; Carmolli M; Wright PF; Norton EB; Kirkpatrick BD
    Vaccine; 2022 Apr; 40(19):2705-2713. PubMed ID: 35367069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine with dmLT adjuvant protects human volunteers against virulent experimental ETEC challenge.
    Harro C; Louis Bourgeois A; Sack D; Walker R; DeNearing B; Brubaker J; Maier N; Fix A; Dally L; Chakraborty S; Clements JD; Saunders I; Darsley MJ
    Vaccine; 2019 Mar; 37(14):1978-1986. PubMed ID: 30797634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial.
    Qadri F; Akhtar M; Bhuiyan TR; Chowdhury MI; Ahmed T; Rafique TA; Khan A; Rahman SIA; Khanam F; Lundgren A; Wiklund G; Kaim J; Löfstrand M; Carlin N; Bourgeois AL; Maier N; Fix A; Wierzba T; Walker RI; Svennerholm AM
    Lancet Infect Dis; 2020 Feb; 20(2):208-219. PubMed ID: 31757774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic fusions of a CFA/I/II/IV MEFA (multiepitope fusion antigen) and a toxoid fusion of heat-stable toxin (STa) and heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC) retain broad anti-CFA and antitoxin antigenicity.
    Ruan X; Sack DA; Zhang W
    PLoS One; 2015; 10(3):e0121623. PubMed ID: 25803825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and preclinical evaluation of a freeze-dried formulation of a novel combined multivalent whole-cell/B-subunit oral vaccine against enterotoxigenic Escherichia coli diarrhea.
    Borde A; Ekman A; Larsson A; Carlin N; Holmgren J; Tobias J
    Eur J Pharm Biopharm; 2016 Nov; 108():18-24. PubMed ID: 27485398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal Immune Responses Against an Oral Enterotoxigenic Escherichia coli Vaccine Evaluated in Clinical Trials.
    Svennerholm AM; Lundgren A; Leach S; Akhtar M; Qadri F
    J Infect Dis; 2021 Dec; 224(12 Suppl 2):S821-S828. PubMed ID: 34550392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enterotoxigenic Escherichia coli Adhesin-Toxoid Multiepitope Fusion Antigen CFA/I/II/IV-3xSTa
    Nandre R; Ruan X; Lu T; Duan Q; Sack D; Zhang W
    Infect Immun; 2018 Mar; 86(3):. PubMed ID: 29263112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Passive antibodies derived from intramuscularly immunized toxoid fusion 3xSTa
    Nandre RM; Duan Q; Wang Y; Zhang W
    Vaccine; 2017 Jan; 35(4):552-556. PubMed ID: 28017433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of recombinant Lactobacillus casei-expressing F4 (K88) fimbrial adhesin FaeG in conjunction with a heat-labile enterotoxin A (LTAK63) and heat-labile enterotoxin B (LTB) of enterotoxigenic Escherichia coli as an oral adjuvant in mice.
    Yu M; Qi R; Chen C; Yin J; Ma S; Shi W; Wu Y; Ge J; Jiang Y; Tang L; Xu Y; Li Y
    J Appl Microbiol; 2017 Feb; 122(2):506-515. PubMed ID: 27860074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the reactogenicity, adjuvanticity and antigenicity of LT(R192G) and LT(R192G/L211A) by intradermal immunization in mice.
    Maciel M; Smith M; Poole ST; Laird RM; Rollenhagen JE; Kaminski RW; Wenzel H; Bourgeois AL; Savarino SJ
    PLoS One; 2019; 14(11):e0224073. PubMed ID: 31682624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the immunogenicity and protective efficacy of a recombinant CS6-based ETEC vaccine in an Aotus nancymaae CS6 + ETEC challenge model.
    Ramakrishnan A; Joseph SS; Reynolds ND; Poncet D; Maciel M; Nunez G; Espinoza N; Nieto M; Castillo R; Royal JM; Poole S; McVeigh A; Rollenhagen JE; Heinrichs J; Prouty MG; Simons MP; Renauld-Mongénie G; Savarino SJ
    Vaccine; 2021 Jan; 39(3):487-494. PubMed ID: 33357957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of mucosal and systemic immune responses against the common O78 antigen of an oral inactivated ETEC vaccine in Bangladeshi children and infants.
    Svennerholm AM; Qadri F; Lundgren A; Kaim J; Rahman Bhuiyan T; Akhtar M; Maier N; Louis Bourgeois A; Walker RI
    Vaccine; 2022 Jan; 40(2):380-389. PubMed ID: 34772542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.